# Clinical Utility of the Molecular Microscope Diagnostic System in a Real-World Transplant Cohort: Moving Towards a New Paradigm

3

Andrea Fernandez Valledor<sup>1</sup> \* MD, Cathrine M. Moeller<sup>1</sup> \* MD, MSc, Gal Rubinstein<sup>1</sup>, 4 Salwa Rahman<sup>1</sup> MD, Daniel Oren<sup>1</sup> MD MSc, Julia Baranowska<sup>1</sup> MD, Changhee Lee<sup>1</sup> 5 BS, Ruben Salazar<sup>1</sup> MD, Carolyn Hennecken<sup>1</sup> MD, Afsana Rahman<sup>1</sup> MD, Boaz 6 Elad<sup>1</sup> MD, Dor Lotan<sup>1</sup> MD, Ersilia M. DeFilippis<sup>1</sup> MD, Adil Yunis<sup>1</sup> MD, Justin Fried<sup>1</sup> 7 MD, Jayant Raihkelkar<sup>1</sup> MD, Kyung T. Oh<sup>1</sup>, David Bae<sup>1</sup> MD, Edward Lin<sup>1</sup> MD, Sun 8 Hi. Lee<sup>1</sup> MD, Matthew Regan<sup>2</sup> MSN, MD, Melana Yuzelpolskaya<sup>1</sup> MD, Paolo 9 Colombo<sup>1</sup> MD, David T. Majure<sup>2</sup> MD, Farhana Latif <sup>1</sup> MD, Kevin D. Clerkin <sup>1</sup> MD, 10 Gabriel T. Sayer<sup>1</sup> \*\* MD, Nir Uriel<sup>1</sup> \*\* MD, MSc. 11

12

13 \*Equally contributed

14 \*\* Co-senior authorship

<sup>1</sup>Division of Cardiology. Advanced Cardiac Care. Columbia University Irving Medical
 Center.

<sup>2</sup>Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York,
New York.

19

The institution receives grant support from Abbott, Abiomed and CareDx. Dr. Uriel is on the medical advisory board for Livemetric, Leviticus and Revamp. Dr. Sayer has been a consultant for Abbott and is on the medical advisory board for CareDx. K.J.C receives NIH grant support (K23HL148528). D.B. receives institutional grant support from Abiomed.

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 26 **RUNNING TITLE:** Clinical utility of the Molecular Microscope Diagnostic System in
- 27 Heart Transplantation
- 28
- 29 **Corresponding author:**
- 30 Nir Uriel MD, MSc. FACC.
- 31 Professor of Medicine.
- 32 Director of New York Presbyterian Heart Failure,
- 33 Heart Transplant and Mechanical Circulatory Support Programs.
- 34 Columbia University Irving Medical Center. Weill Cornell Medicine.
- 35 Email: <u>nu2126@cumc.columbia.edu</u>
- 36 X: @NirUrielMD
- 37
- 38 WORD COUNT: 4085
- 39
- 40
- 41
- 42
- 43
- 44
- . .
- 45
- 46
- 47
- 48
- 49
- т)
- 50

#### 51 **ABSTRACT**

52 **Objectives:** To evaluate the clinical implications of adjunctive molecular gene 53 expression analysis (MMDx) of biopsy specimens in heart transplant (HT) recipients 54 with suspected rejection.

Introduction: Histopathological evaluation remains the standard method for rejection diagnosis in HT. However, the wide interobserver variability combined with a relatively common incidence of "biopsy-negative" rejection has raised concerns about the likelihood of false-negative results. MMDx, which uses gene expression to detect early signs of rejection, is a promising test to further refine the assessment of HT rejection.

61 Methods: Single-center prospective study of 418 consecutive for-cause 62 endomyocardial biopsies performed between November 2022 and May 2024. Each biopsy was graded based on histology and assessed for rejection patterns using 63 64 MMDx. MMDx results were deemed positive if borderline or definitive rejection was present. The impact of MMDx results on clinical management was evaluated. 65 66 Primary outcomes were 1-year survival and graft dysfunction following MMDx-guided clinical management. Secondary outcomes included changes in donor-specific 67 antibodies, MMDx gene transcripts, and donor-derived cell-free DNA (dd-cfDNA) 68 69 levels.

**Results**: We analyzed 418 molecular samples from 237 unique patients. Histology identified rejection in 32 cases (7.7%), while MMDx identified rejection in 95 cases (22.7%). Notably, in 79 of the 95 cases where MMDx identified rejection, histology results were negative, with the majority of these cases being antibody-mediated rejection (62.1%). Samples with rejection on MMDx were more likely to show a

combined elevation of dd-cfDNA and peripheral blood gene expression profiling than those with borderline or negative MMDx results (36.7% vs 28.0% vs 10.3%; p<0.001). MMDx results led to the implementation of specific antirejection protocols or changes in immunosuppression in 20.4% of cases, and in 73.4% of cases where histology was negative and MMDx showed rejection. 1-year survival was better in the positive MMDx group where clinical management was guided by MMDx results (87.0% vs 78.6%; log rank p=0.0017).

Conclusions: In our cohort, MMDx results more frequently indicated rejection than
 histology, often leading to the initiation of antirejection treatment. Intervention guided
 by positive MMDx results was associated with improved outcomes.

85

Abbreviations: HT: heart transplantation; MMDx: Molecular Microscope Diagnostic
 System; EMB: endomyocardial biopsy; dd-cfDNA: donor-derived cell free DNA,
 pGEP: peripheral gene-expression profiling; DSA: donor specific antibodies. ABMR:
 antibody-mediated rejection on MMDx; TCMR: T-cell mediated rejection on MMDx;
 pAMR pathological antibody-mediated rejection; ACR: acute cellular rejection
 (histology).

92

#### 93 **INTRODUCTION:**

Heart transplantation (HT) remains the preferred therapy for patients with advanced heart failure who do not exhibit features of myocardial recovery and lack contraindications (1). Despite refinements in immunosuppressive schemes, allograft rejection remains a compelling cause of morbidity in the initial stages, and one of the leading determinants of long-term graft survival (1-4). Although the gold standard for rejection diagnosis is the histological assessment of the endomyocardial biopsy

(EMB), its reliability is hindered by the reliance on expertise in pattern recognition,
 the lack of consensus on complement-independent antibody-mediated rejection

102 pathways, and the high prevalence of biopsy-negative rejection (5-8).

103

Over the past few years, we have witnessed a rise in the adoption of novel rejection 104 105 surveillance tools, such as donor-derived cell-free DNA (dd-cfDNA) and the 106 Molecular Microscope Diagnostic System (MMDx, One Lambda, CA) (6,9-13). These 107 advancements have enabled the early detection of rejection even before histological 108 changes become apparent (14). As a result, physicians increasingly encounter 109 situations with discrepant results in which the role of the clinician becomes more 110 indispensable than ever, as multiple variables need to be incorporated into 111 therapeutic decision-making. The molecular diagnosis provided by MMDx offers a 112 probabilistic assessment of rejection independent of histological findings, enhancing 113 diagnostic accuracy with high precision (6). Supervised molecular classifiers have 114 demonstrated superior predictive ability for molecular rejection, with areas under the 115 curve > 0.87, compared to histologic rejection < 0.78 (11). Previous research has 116 examined the correlation between MMDx and histology as well as the association 117 between dd-cfDNA and MMDx-rejection related transcripts (15-18). However, there 118 is still limited understanding of how integrating MMDx into clinical decision-making 119 processes can impact patient care. Therefore, we aimed to assess the clinical utility 120 of MMDx analysis in a cohort of heart transplant recipients undergoing EMB for clinical indication. 121

122

123

124 **METHODS**:

## 125 Study design and population:

126 Consecutive HT recipients that underwent EMB due to suspected rejection between November 2022 and May 2024 at our institution were prospectively included. This 127 128 study was approved by the Institutional Review Board with a waiver of informed 129 consent. Causes for biopsy included: 1) clinical symptoms compatible with rejection 130 (e.g. heart failure symptoms or chest pain); 2) de-novo allograft dysfunction [defined as left ventricular ejection fraction (LVEF) less than 50%, or a decline in LVEF >10% 131 132 from the previous echocardiography (TTE); 3) elevated dd-cfDNA levels (≥0.12%, 133 Allosure, CareDX); 4) de novo or rising donor specific antibodies (DSA), 5) elevated 134 biomarkers (NT-proBNP and/or high-sensitivity troponin T), and/or 6) follow-up on 135 recently treated rejection. EMB was performed in the standard fashion with 5-6 136 samples obtained. Three tissue samples were sent for histological evaluation and 137 immunohistochemistry, 1 sample was sent for immunofluorescence and between 138 one to two samples were sent for molecular analysis (MMDx).

139

#### 140 Data collection:

Baseline characteristics, transplant data information, current immunosuppressive regimen, echocardiography assessment, presence and type of DSA, cardiac biomarkers and hemodynamics at the time of biopsy, were systematically collected for each sample. This also included paired dd-cfDNA levels and peripheral blood gene-expression profiling (pGEP). Viral polymerase chain reactions for Ebstein-Barr virus (EBV), BK and cytomegalovirus (CMV) were also systematically checked at the time of pGEP/ dd-cfDNA screening.

148

149 Non-invasive monitoring:

150 Since 2019, our center has used a non-invasive rejection surveillance protocol in 151 which dd-cfDNA and pGEP testing are standard of care, commencing at the 6th week for dd-cfDNA and at the 8th week for pGEP. These tests are conducted 152 153 monthly during the first-year post-transplant and then shift to a guarterly schedule 154 until the 3rd year post-transplant. After the first two years, additional dd-cfDNA and pGEP samples are collected as clinically indicated. At our institution, positive dd-155 156 cfDNA levels were defined as  $\geq 0.12\%$ . For the purposes of this study, we report 157 results for the  $\ge 0.12\%$  threshold as well as the  $\ge 0.20\%$  threshold, which has been 158 used to define rejection in other studies. We used two thresholds for pGEP positivity: >30 within the first 5 months after transplant and >34 for  $\geq$ 6 months post-transplant. 159 Only dd-cfDNA levels and pGEP results obtained within 31 days of biopsy and those 160 161 from single organ recipients were included in the analysis.

162

163 Donor specific antibodies (DSA):

Our protocol includes the evaluation of DSA at specific intervals: weeks 1, 4, and months 3, 6, 9, 12, followed by every six months after the first year using the Luminex assay. The threshold for antibody detection is set at medium fluorescence intensity (MFI) > 1000. DSA were classified as class I or II antibodies and further categorized based on MFI levels as follows: low (<4000), moderate (4000-10000), high (10000-20000) and very high (>20000). We also routinely screened patient for major histocompatibility complex class I chain-related gene A (MIC-A) antibodies.

171

172 *Hemodynamics:* 

173 At the time of EMB, right heart catheterization was routinely performed, with 174 standard assessment of hemodynamics and using the assumed Fick method to

calculate cardiac output. Abnormal hemodynamics were defined as a cardiac index
<2.2 l/min\*m<sup>2</sup>, mean pulmonary pressures > 24 mmHg, pulmonary capillary wedge
pressure >15 mmHg or right atrial pressure >8 mmHg.

178

179 Histological assessment:

180 Histological evaluation was performed by three pathologists who were blinded to clinical information. All biopsies were routinely evaluated for histopathologic 181 182 evidence of acute cellular rejection (ACR), and antibody-mediated rejection (pAMR). 183 All biopsies were screened for complement deposition (C4d) and intravascular monocyte presence (CD68). Biopsies were graded based on the criteria outlined in 184 185 the International Society of Heart and Lung Transplant (ISHLT) 2004 guidelines (19) 186 for acute cellular rejection and the revised 2013 guidelines for AMR (20-21). Histological rejection was identified as positive if ISHLT grading>1R/1A rejection was 187 present and/or pAMR > 0. In cases where positive results were followed by 188 189 treatment, a repeat biopsy was typically conducted within two weeks for ACR and 190 within four to eight weeks after antibody-mediated rejection treatment.

191

192 Molecular Microscope Diagnostic System (MMDx):

193 MMDx is a central diagnostic system that uses microarrays to measure mRNA levels 194 in transplants biopsies. Archetype scores for normal (NRI), T-cell mediated rejection 195 (TCMR), antibody-mediated rejection (ABMR) and injury that go from 0 to 1 are 196 given for each biopsy. The models translate these archetypes into rejection 197 probabilities. Generally, a definitive diagnosis is established when the probability 198 exceeds 0.6. Intermediate cases in which the inflammation does not reach the extent 199 to be considered as definite rejection are defined as borderline rejection. The MMDx 200 report provides additional molecular data including pathogenesis-based transcript set 201 scores and transcript expression scores relating to the different rejection subtypes and parenchymal injury. For each score, a normal limit is given, defined as the 95<sup>th</sup> 202 203 percentile score in the normal biopsies (6). "Rejection" or "definitive rejection" on MMDx was defined as the presence of TCMR, ABMR, or mixed rejection. "Positive" 204 205 MMDx results included borderline rejection along with definitive rejection due to the 206 similarities of borderline cases to those with definitive rejection. Cases classified as 207 normal (NRI) or with parenchymal injury were considered negative MMDx.

208

## 209 Clinical decision making:

The multidisciplinary care team integrated clinical presentation, histological and molecular results, dd-cfDNA levels and pGEP scores, biomarkers, graft function and hemodynamics, presence and trajectory of DSA, history of rejection episodes and past treatments to determine subsequent treatment plans. The final decision is not protocolized and is left to the discretion of clinicians. **Figure 1.** 

215

#### 216 Outcomes:

We evaluated how the implementation of MMDx influenced clinical management and its impact on outcomes. Specifically, we compared 1-year survival rates and the incidence of graft dysfunction based on MMDx results and subsequent MMDxguided interventions. Graft dysfunction was defined as a new occurrence of LVEF <50% or a decline in LVEF >10% during the follow-up period. Patients already exhibiting graft dysfunction at the time of MMDx were censored from this analysis.

Secondary outcomes included changes in MFI levels of DSA, MMDx-transcripts, and dd-cfDNA in the subsequent screening following treatment adjustment based on MMDx results. Improvement in DSA was defined as a reduction in MFI category (e.g., from high to moderate) or a 25% reduction in MFI levels if the baseline MFI was >4000. We also monitored the development of de novo DSA if MFI was >2000. Additionally, we measured changes in kidney function, and infection rates within three months following the increase in immunosuppression.

230

#### 231 Data Analysis and Statistical Methods:

232 Statistical analysis was performed using R Core Team (2020): A language and environment for statistical computing, R Foundation for Statistical Computing, 233 234 Vienna, Austria version 4.1.3. Scatter and bar plots were created using Microsoft 235 Office Excel. The Shapiro-Wilk test was performed on all continuous variables to 236 determine normality. Gaussian distributed continuous variables were reported as 237 means and standard deviations. Non-gaussian distributed variables were reported as 238 median and interguartile range. Categorical variables were summarized as n (%) and 239 compared using Fisher's Exact Test or chi square test as appropriate for 240 independent variables or McNemar's test for paired variables. Parametric variables 241 were compared using independent two-sample or paired sample t-test as appropriate. Non-parametric variables were compared using Kruskal-Wallis test for 242 243 independent samples, and Friedman test for dependent samples. A p-value of 0.05 was considered statistically significant. Survival analysis was conducted using the 244 245 Kaplan Meier method to identify overall survival and freedom from graft dysfunction 246 at 1- year stratified based on the MMDx result and management. A log-rank test was 247 employed to evaluate the difference between the survival curves.

248

#### 249 **RESULTS**:

During the study period, 441 paired histology and MMDx EMB samples were identified. Of these, 23 were excluded as they were performed as part of our surveillance monitoring protocol. The final cohort consisted of 418 samples from 248 heart transplant recipients. **Figure 2.** 

254

#### 255 Baseline Characteristics

Patient baseline characteristics are represented in **Table 1S.** The leading indication for biopsy was an elevated dd-cfDNA levels in 40.2% of the cases, followed by symptoms (21.1%), rising DSA level (13.4%), de-novo or worsening allograft dysfunction (12.2%), follow-up on recently treated rejection (11.2%) and elevated biomarkers (1.9%).

261

## 262 Concordance and Discordance between Histology and MMDx

Concordance and discordance between histology and MMDx are shown in Figure 263 **3A**. Histological analysis detected rejection in 32 samples (7.7%), whereas MMDx 264 265 identified rejection in 95 samples (22.7%). The overall concordance between histology and MMDx was 76.8% (S=318), primarily driven by negative concordance 266 267 (73.2%; S=303). Of the 96 samples with discordant results (23.2%), 79 samples (82.3%) had negative histology, but rejection detected by MMDx. In this group, 268 MMDx identified ABMR in 48 samples (60.7%), TCMR in 26 samples (32.9%), and 269 270 mixed rejection in 5 samples (6.3%). Figure 3A. Of the 17 cases (16.0%) with positive histology and negative MMDx, 9 (53.0%) exhibited low-grade rejection on 271 272 histology (2 cases of 1B rejection and 7 cases of pAMR=1i). Table 2S.

A trend towards a higher prevalence of DSA was observed when both histology and MMDx indicated rejection (77.3%), compared to cases where only histology (64.7%) or only MMDx (44.3%) indicated rejection (p=0.07). However, the presence of moderate-level or greater DSA (MFI >4000) was more common when both techniques detected rejection compared to cases where only one method detected rejection (p<0.001). **Table 2S.** 

279

280

#### 281 Concordance and Discordance between dd-cfDNA and MMDx

282 Concordance and discordance between dd-cfDNA levels at 0.12% and 0.20% 283 thresholds with MMDx are depicted in **Figures 3B** and **3C** respectively. When 284 comparing positive MMDx results to dd-cfDNA levels, the concordance was higher 285 using the 0.20% threshold (70.1%) compared to the 0.12% threshold (64.6%). This 286 improvement in concordance was mainly due to an increase in negative 287 concordance at the higher threshold.

288

#### 289 MMDx results

Samples in which MMDx showed rejection were further out from transplant and had a higher prevalence of prior treated rejections than samples with borderline or negative MMDx results. **Table 1.** Positive dd-cfDNA results were observed in 92.6% and 83.8% of cases with rejection on MMDx at  $\ge 0.12\%$  and  $\ge 0.20\%$  thresholds, respectively. dd-cfDNA levels were also higher in cases of definitive rejection (0.61% [0.27-1.40]) compared to those with borderline (0.33% [0.19-0.59]) or negative MMDx results (0.20% [0.14-0.34]; p<0.001). **Figure 1S**. That contrast with histology,

where dd-cfDNA levels did not significantly differ between rejection and no-rejection samples (0.44% [0.20-1.70] vs. 0.24% [0.11-0.52]; p=0.06).

299 When combined with pGEP, samples with rejection on MMDx had higher rates of combined (+)pGEP/(+)dd-cfDNA (36.7%) compared to samples with borderline 300 301 (28.0%) or negative MMDx results (10.3%); p<0.001. Specifically, samples with 302 (+)pGEP/(+)dd-cfDNA had three times higher rates of definitive rejection detected by MMDx (36.7% vs 10.3%; p<0.001). Furthermore, when compared to samples with (-303 304 )pGEP/(-)dd-cfDNA, the presence of (+)pGEP/(+)dd-cfDNA was associated with a 305 fourfold increase in the rates of definitive rejection on MMDx (36.7% vs 8.3%; 306 p<0.001). **Table 2**.

307 The prevalence of positive DSA and moderate strength or greater DSA was similar 308 between cases of definitive rejection and borderline MMDx results (49.5% vs. 57.1%; p = 0.30 and 28.4% vs. 34.5%; p = 0.38, respectively). However, these prevalences 309 310 were significantly higher compared to samples with negative MMDx (p=0.045 for 311 DSA and p=0.02 for higher MFI); **Table 2**. The presence of de-novo graft dysfunction (p=0.82) or abnormal hemodynamics (p=0.34) at the time of biopsy was similar 312 313 between the groups. **Table 3S**. Samples with rejection were more commonly from 314 patients receiving belatacept (27.4% vs 10.7% vs 7.9%; p<0.001) or undergoing 315 extracorporeal photopheresis (ECP) (7.4% vs 3.6% vs 0.8%; p=0.006) as part of 316 their immunosuppressive regimen compared to samples with borderline or negative MMDx results. Table 3S. 317

318

319 MMDx and clinical decision making:

320 The addition of MMDx results altered clinical management in 20.3% of cases 321 (84/414). Figure 4. In instances of negative histology and rejection on MMDx (N=79), immunosuppressive therapy was altered in 73.4% of cases (58/79). 322 323 Specifically, 17 patients (29.3%) underwent acute ABMR protocols, which included bortezomib, plasmapheresis (PLEX), and intravenous immunoglobulin (IVIg) in 11 324 325 cases; thymoglobulin, PLEX, IVIg, and rituximab in 2 cases; or rituximab and IVIg in 326 4 cases. Sixteen patients (27.6%) received pulse steroids alone, and 25 patients 327 (43.1%) had their chronic immunosuppression regimen intensified. In 15 patients, a 328 new drug or therapy was introduced (ECP in 6 patients, IVIg in 4 patients, 329 mycophenolate in 3 patients and reinitiation of calcineurin inhibitor therapy in 2 330 patients). The remaining 10 patients had the dosing of existing therapies increased. 331 Among the samples with borderline rejection, 18 (85.7%) patients had their 332 immunosuppression increased, 2 (9.5%) received steroid pulse and in 1 case (4.8%) the patient was not weaned off prednisone. All the cases with changes to treatment 333 334 had elevated dd-cfDNA levels.

Conversely, in cases where histological rejection was present, the absence of rejection on MMDx also influenced clinical decisions. Specifically, in 3 out of 17 such cases, we either abstained from treatment or adopted a less aggressive approach based on MMDx results. This included 2 cases of pAMR 1i and 1 case of pAMR 2. **Figure 4**.

340

#### 341 Survival and graft function

At the 1-year follow-up, patients who had positive MMDx results and whose treatment was guided by those results (N=81) showed a survival rate of 87.0%, which was comparable to the survival rate of patients with negative MMDx results

(89.0%). Conversely, among patients with positive MMDx results who did not undergo a change in therapy (N=98), the survival rate was significantly lower at 78.6% (log-rank p=0.02). **Figure 6**. No significant differences were observed in the occurrence of graft dysfunction between the groups (log-rank test; p = 0.66).

349

350 Change in dd-cfDNA, DSA levels, and incidence of rejection during follow-up

351 An improvement in dd-cfDNA levels, defined as a 25% reduction following treatment, 352 was observed in 76% of patients who were treated based on MMDx results. 353 Conversely, only 36% of patients with positive MMDx who did not receive treatment 354 showed a reduction in dd-cfDNA levels (p=0.04). Improvement in DSA was observed 355 in 28% of cases in the active intervention group compared to 10% in the group 356 without active treatment (p=0.012). The median time from MMDx to follow-up DSA was comparable between the groups: 29 days [19-58] in the intervention group vs 36 357 358 days [24-73.5] in the non-intervention group (p=0.126). The rates of rejection during 359 follow-up were similar between the groups, both by histology (6.25% vs 6.45%; p=0.66) and by MMDx (33.3% vs 37.5%; p=0.91). 360

361

362 Change in gene expression transcripts:

363 32 episodes of rejection on MMDx with a follow-up MMDx were identified. Following 364 treatment, cases of TCMR showed significant improvement in TCMR's rejection 365 scores, all TCMR-related transcripts (**Figure 5; Table 4S**), and injury-related 366 transcripts (QCMAT and HT1) on the following MMDx sample. Similarly, in cases of 367 ABMR, all transcript-related clusters associated with ABMR (**Figure 5, Table 5S**) 368 decreased after treatment. **Figure 2S** represents the remaining transcript set.

369

#### 370 Kidney function

Median eGFR values at the time of biopsy for patients who received treatment based on MMDx were 72.5 mL/min/1.73m<sup>2</sup> [50.3 – 90.0]. No significant differences were found in eGFR values at 1 month (75.7 [49.0 – 90.0]) or 3 months during follow-up (70.0 [51.3 – 90.0]; p=0.74). **Figure 3S.** 

375

#### 376 Infection and malignancy

377 Among the 81 episodes of rejection treated based on MMDx results, 5 patients 378 (6.2%) experienced a subsequent infection within 3 months requiring hospitalization. 379 The infections included line-associated bacteremia related to ECP, infectious 380 diarrhea, urinary tract infection, and soft-tissue cellulitis. Additionally, 7 patients 381 (8.6%) experienced active viremia post-treatment, that did not require further intervention: 3 patients had BK viremia, 3 had EBV viremia, and 1 had CMV viremia, 382 with a median viral load of 340 [130-385] copies/mL. One patient, who had initially 383 384 been treated with pulse steroids due to TCMR was diagnosed with localized lung adenocarcinoma 13 months later. 385

386

#### 387 **DISCUSSION:**

To our knowledge, this is the first evaluation of the clinical utility of MMDx in a cohort of heart transplant recipients with suspected rejection. Our major findings are as follows: 1) MMDx detected rejection three times more frequently than histology; 2) A pattern in dd-cfDNA levels was observed across cases with definitive, borderline, and negative MMDx results; the rates of rejection detected by MMDx were four times higher when both dd-cfDNA and pGEP levels were elevated; 3) Overall, immunosuppression was modified in response to MMDx in 20% of the cases and in 395 73% of the instances where histology was negative and MMDx showed rejection; 4)396 For patients with a positive MMDx, survival was superior in patients who underwent397 treatment guided by MMDx compared to those who did not receive treatment based398 on MMDx findings; 5) In the active treatment group, both dd-cfDNA levels, DSA and399 MMDx rejection-related transcripts showed significant improvement during follow-up.

400 While histological assessment has been pivotal in understanding rejection patterns 401 and crucial for the evolution of transplantation, its limitations have become evident 402 (5,7). The incorporation of new tools like dd-cfDNA and MMDx, combined with the 403 high incidence of biopsy-negative rejection in clinical practice, has highlighted the 404 need to reassess how we determine the presence of rejection in the contemporary 405 era (6, 22-23). Several studies have shown that dd-cfDNA elevations precede 406 histological rejection and that elevated dd-cfDNA levels correlates more strongly with 407 molecular diagnosis than with conventional histology (9, 16, 18). This highlights the 408 superior diagnostic precision of MMDx, especially in cases where there are 409 discrepancies between histological and molecular findings, underscoring the enhanced accuracy of MMDx over histology (11, 22, 25). The recently published 410 411 SHORE (Surveillance HeartCare Outcomes Registry) (24) highlighted the diagnostic 412 utility of combining dd-cfDNA and pGEP in identifying ACR on histology. Notably, 413 only 9.3% of samples with both elevated dd-cfDNA and pGEP showed histological 414 evidence of rejection. Whether these low rates reflect a lack of specificity of dd-415 cfDNA or the low sensitivity of histology for detecting rejection remains a subject of debate. Our study found that the utilization of MMDx resulted in a rejection rate 416 417 nearly three times higher than traditional histology (22.7% vs 7.7%). This significant 418 increase suggests that MMDx may be more sensitive in detecting rejection than 419 conventional histology. Moreover, samples with rejection identified by MMDx 420 exhibited higher rates of positive dd-cfDNA results and elevated dd-cfDNA levels 421 compared to those with negative MMDx results. This contrasts with histology, where dd-cfDNA levels did not significantly differ between rejection and no-rejection states. 422 423 Interestingly, a trend in dd-cfDNA levels was observed across definitive rejection, 424 borderline rejection, and negative MMDx cases, suggesting that rejection might be 425 better understood as a continuous spectrum of myocardial injury rather than a binary condition. This is further supported by the observation that samples with rejection 426 427 detected by both MMDx and histology exhibited the highest dd-cfDNA levels 428 compared to samples where only one method detected rejection. This implies that 429 MMDx may be more effective in capturing this continuum of myocardial injury than 430 traditional histology, potentially providing a more nuanced and accurate assessment 431 of rejection.

432 The similarity in the presence of DSA and higher MFI antibody titers between cases 433 of definitive and borderline rejection, despite lower levels of dd-cfDNA and rejection 434 rates on histology in borderline cases, suggests that borderline changes may represent an early stage of rejection rather than a benign finding (14,18). Indeed, in 435 436 our cohort, cases of borderline rejection were followed by treatment in approximately 437 1 out of 3 cases. This continuum perspective aligns with findings from the Trifecta-438 Heart study (18), which reported higher dd-cfDNA levels in definitive rejection cases 439 compared to those with borderline changes or negative MMDx. These results mirror 440 previous observations from kidney biopsies (17,25), reinforcing the correlation between non-invasive markers and molecular diagnostics. 441

442

In our cohort, the presence of a combined (+)pGEP/(+)dd-cfDNA was associated with a 4-fold increase in the rates of rejection on MMDx compared to samples with both negative results (36.7% vs 8.3%). Likewise, a (+)pGEP/(+)dd-cfDNA was nearly three times more frequent in samples with borderline rejection than those with normal MMDx (28.0% vs 10.3%; p<0.001). These data suggest that the combination of both tests may provide an improved performance over each test alone, similar to what was previously described in the SHORE registry (24).

450

In cases where histology was negative and MMDx showed rejection, ABMR was detected nearly twice as frequently as TCMR. This finding aligns with the INTERHEART study, which demonstrated that many biopsies initially classified as negative or having low-grade rejection based on histology actually exhibited some ABMR changes (14).

456 In our cohort, in nearly 75% of cases where histology was negative and MMDx detected rejection, patients were subsequently treated based on MMDx results. 29% 457 of those cases received ABMR specific protocols. The increasing detection of ABMR 458 459 is of particular interest, given the well-known limitations of histology in detecting 460 pAMR. Improving the detection of ABMR may provide a key to addressing incipient 461 inflammation and injury, potentially ameliorating or averting the progression of cardiac allograft vasculopathy (CAV). Although our study was underpowered to 462 463 evaluate the impact of interventions on CAV outcomes due to the reduced follow-up time, patients whose treatment was guided by positive MMDx results demonstrated 464 improved 1-year survival rates. In these cases, treatment was followed by a 465 466 significant reduction in dd-cfDNA levels, DSA strength and MMDx-rejection

467 transcripts. Importantly, this treatment approach did not adversely impact kidney
468 function, and the rates of clinically relevant infectious complications were acceptable.

Taken together, these findings highlight the potential role of MMDx in guiding therapeutic interventions and question whether histology should remain the gold standard for rejection diagnosis. Nevertheless, longer follow-up and carefully designed trials are necessary to corroborate our findings. Future research should focus on whether acting on early signs of rejection will play a crucial role in preserving graft function and preventing the initiation and/or progression of CAV.

This study has several limitations. First, this is a single-center analysis which may limit its external generalizability. Second, we did not have a single pathologist review all histology, but the pathologists were blinded to MMDx results and clinical data in all cases. Third, dd-cfDNA/pGEP levels were not sent concurrently with biopsy in most cases although we limited the separation between these labs and MMDx to 31 days. Lastly, the response to MMDx results was not protocolized and was left up to the discretion of individual clinicians.

482

483 **Conclusion:** Our results highlight the potential of MMDx to provide complementary 484 information aiding in the diagnosis of allograft rejection and guiding clinical 485 management. These data raise concerns about whether histology should continue to 486 be used as the gold standard for rejection surveillance.

487

488

489 **Conflict of interest:** The institution receives grant support from 490 Abbott, Abiomed and CareDx. Dr. Uriel is on the medical advisory board

491 for Livemetric, Leviticus and Revamp. Dr. Sayer has been a consultant for Abbott 492 and is on the medical advisory board for CareDx. K.J.C receives NIH grant support (K23HL148528). D.B. receives institutional grants support from Abiomed. All other 493 494 authors report non-financial contributions or conflicts of interest. Dr. Moeller receives a grant from ISHLT and CareDx. This study was approved by the Columbia 495 496 University Institutional Review Board with a waiver of informed consent. 497 Author contributions: all authors contributed significantly to the production of this 498 499 manuscript and all authors have offered final approval of the submitted version. 500 501 Acknowledgements: Andrea Fernandez Valledor received grant support by the 502 Alfonso Martin Escudero Foundation. 503 504 505 506 507 REFERENCES 508 509 1. Koomalsingh K, Kobashigawa JA. The future of cardiac transplantation. Ann 510 Cardiothorac Surg. 2018;7:135-142. 511 2. Mehra MR. Heart transplantation at 50. Lancet. 2017;390:e43-e45. 3. Khush KK, Hsich E, Potena L, Cherikh WS, Chambers DC, Harhay MO, et al. The 512 513 International Thoracic Organ Transplant Registry of the International Society for 514 Heart and Lung Transplantation: Thirty-eighth adult heart transplantation report — 2021; Focus on recipient characteristics. J Hear Lung Transplant. Elsevier Inc.; 515 516 2021;40:1035-49. 4. Colvin MM, Cook JL, Chang P, Francis G, Hsu DT, Kiernan MS, et al. Antibody-517 518 mediated rejection in cardiac transplantation: Emerging knowledge in diagnosis and

519 management: A scientific statement from the American Heart Association: Endorsed

520 by the international society for heart and lung transplantation. Circulation. 2015.

521 5. Shanes JG, Ghali J, Billingham ME, Ferrans VJ, Fenoglio JJ, Edwards WD, et al.

522 Interobserver variability in the pathologic interpretation of endomyocardial biopsy

- 523 results. Circulation. 1987 Feb;75(2):401–5.(6)
- 6. Halloran PF, Potena L, Van Huyen JD, et al. Building a tissue-based molecular
  diagnostic system in heart transplant rejection: the heart Molecular Microscope
  Diagnostic (MMDx) System. J Heart Lung Transplant. 2017;36:1192–1200.
- 527 7. Furness PN, Taub N, Assmann KJ, et al. International variation in histologic 528 grading is large, and persistent feedback does not improve reproducibility. Am J 529 Surg Pathol. 2003;27:805–810.
- 8. Crespo-Leiro MG, Zuckermann A, Bara C, et al. Concordance among pathologists
  in the second cardiac allograft rejection gene expression observational study
  (CARGO II). Transplantation. 2012;94:1172–1177.
- 9. Madill-Thomsen KS, Reeve J, Aliabadi-Zuckermann A, et al. Assessing the
  Relationship Between Molecular Rejection and Parenchymal Injury in Heart
  Transplant Biopsies. *Transplantation*. 2022;106:2205.
- 10. Halloran PF, Madill-Thomsen KS. The Molecular Microscope Diagnostic System:
  Assessment of Rejection and Injury in Heart Transplant Biopsies. Transplantation.
  2023 Jan 1;107(1):27–44.
- 539 11. Parkes MD, Aliabadi AZ, Cadeiras M, et al. An integrated molecular diagnostic
  540 report for heart transplant biopsies using an ensemble of diagnostic algorithms. J
  541 Heart Lung Transplant. 2019;38:636–646.
- 542 12. Khush KK, Patel J, Pinney S, Kao A, Alharethi R, DePasquale E, Ewald G,
- 543 Berman P, Kanwar M, Hiller D, Yee JP, Woodward RN, Hall S, Kobashigawa J.

544 Noninvasive detection of graft injury after heart transplant using donor-derived cell-

545 free DNA: A prospective multicenter study. Am J Transplant. 2019

13. Agbor-Enoh S, Shah P, Tunc I, Hsu S, Russell S, Feller E, et al. Cell-Free DNA 546 547 to Detect Heart Allograft Acute Rejection. Circulation. 2021 Mar 23:143(12):1184-97. 14. Halloran PF, Madill-Thomsen K, Aliabadi-Zuckermann AZ, et al. Many heart 548 549 transplant biopsies currently diagnosed as no rejection have mild molecular 550 antibody-mediated rejection-related changes. J Heart Lung Transplant. 551 2022;41:334-344.

15. Alam A, Van Zyl J, Paul Milligan G, Michelle McKean S, Patel R, Anne Hall S.
Evolving the surveillance and workup of heart transplant rejection: A real-world
analysis of the Molecular Microscope Diagnostic System. Am J Transplant. 2022
Oct;22(10):2443–50.

16. Lee DH, Usmani A, Wu R, et al. Relationship Between Donor Derived Cell-Free
DNA and Tissue-Based Rejection-Related Transcripts In Heart Transplantation. J
Heart Lung Transplant. 2024:S1053-2498(24)00055-X.

17. Halloran PF, Reeve J, Madill-Thomsen KS, et al.; Trifecta Investigators. The
Trifecta study: comparing plasma levels of donor-derived cell-free DNA with the
molecular phenotype of kidney transplant biopsies. J Am Soc Nephrol. 2022;33:387–
400.

18. Halloran PF, Reeve J, Mackova M, Madill-Thomsen KS, Demko Z, Olymbios M,
Campbell P, Melenovsky V, Gong T, Hall S, Stehlik J. Comparing Plasma Donorderived Cell-free DNA to Gene Expression in Endomyocardial Biopsies in the
Trifecta-Heart Study. Transplantation. 2024

567 19. Billingham M, Kobashigawa JA. The revised ISHLT heart biopsy grading scale. J
568 Heart Lung Transplant. 2005;24:1709.

20. Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart
and Lung Transplantation Working Formulation for the standardization of
nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart
transplantation. J Heart Lung Transplant. 2013;32:1147–1162.

573 21. Berry GJ, Angelini A, Burke MM, et al. The ISHLT working formulation for
574 pathologic diagnosis of antibody-mediated rejection in heart transplantation:
575 evolution and current status (2005-2011). J Heart Lung Transplant. 2011;30:601–
576 611.

577 22. De Vlaminck I, Valantine HA, Snyder TM, Strehl C, Cohen G, Luikart H, et al.
578 Circulating Cell-Free DNA Enables Noninvasive Diagnosis of Heart Transplant
579 Rejection. Science Translational Medicine. 2014 Jun 18;6(241):241ra77-241ra77.

580 23. Kim PJ, Olymbios M, Siu A, et al. A novel donor-derived cell-free DNA assay for
581 the detection of acute rejection in heart transplantation. J Heart Lung Transplant.
582 2022;41:919–927.

24. Khush K, Hall S, Kao A, Raval N, Dhingra R, Shah P, Bellumkonda L, 583 Ravichandran A, Van Bakel A, Uriel N, Patel S, Pinney S, DePasquale E, Baran DA, 584 Pinney K, Oreschak K, Kobulnik J, Shen L, Teuteberg J. Surveillance with dual 585 586 noninvasive testing for acute cellular rejection after heart transplantation: Outcomes 587 from the Surveillance HeartCare Outcomes Registry. J Heart Lung Transplant. 2024 588 25. Madill-Thomsen K, Perkowska-Ptasińska A, Böhmig GA, Eskandary F, Einecke 589 G, Gupta G, et al. Discrepancy analysis comparing molecular and histology diagnoses in kidney transplant biopsies. Am J Transplant. 2020 May;20(5):1341-50. 590

591

592

593

- 597 Tables

# **Table 1: sample characteristics stratified by MMDx results**

	Negative (S=239)	Borderline (S=84)	Definitive (S=95)	P-value
Time OHT to MMDX (m)	21.0 [4.00, 78.0]	20.0 [10.0, 49.0]	50.0 [17.8, 94.3]	0.01
Prior ACR	109 (45.6%)	51 (60.7%)	62 (65.3%)	0.002
Prior pAMR	40 (16.7%)	30 (35.7%)	42 (44.2%)	<0.001
LVEF%	53.5 [40.0, 60.0]	55.0 [42.5, 63.0]	55.0 [47.0, 60.0]	0.42
Non-HLA Ab	88 (37.4%)	39 (47.0%)	52 (54.7%)	0.03
NA	5 (2.1%)	1 (1.2%)	0 (0%)	
Positive Histology	8 (3.3%)	9 (10.7%)	15 (15.8%)	0.002
ACR>1R/1A	1 (0.4%)	5 (6.0%)	4 (4.2%)	0.10
pAMR>0	6 (2.5%)	5 (6.0%)	11 (11.6%)	0.02
pAMR>1	4 (1.7%)	3 (3.6%)	4 (4.2%)	0.34
MMDX Results				-
Rejection score	0.14 [0.05-0.25]	0.470 [0.42, 0.56]	0.780 [0.64, 0.93]	
ABMR	0 (0%)	0 (0%)	59 (62.1%)	
TCMR	0 (0%)	0 (0%)	30 (31.6%)	
MIXED	0 (0%)	0 (0%)	6 (6.3%)	
BORDERLINE	0 (0%)	84 (100%)	0 (0%)	
INJURY	30 (12.6%)	0 (0%)	0 (0%)	
NRI	209 (87.4%)	0 (0%)	0 (0%)	

**ABMR:** antibody mediated rejection; **ACR:** acute cellular rejection; **M:** months; **NRI:** 

normal; **pAMR:** pathological antibody mediated rejection; **TCMR:** T-cell mediated

602 rejection.

0	5
~	~
	0

606

607

# 608 Table 2: non-invasive biomarkers and DSA stratified based on MMDx results

	Negative (S=239)	Borderline (S=84)	Definitive (S=95)	P-value
dd-cfDNA≥ 0.12%	75 (58.6%)	48 (82.7%)	63 (92.6%)	<0.001
dd-cfDNA≥ 0.20%	51 (39.8%)	44 (75.9%)	57 (83.8%)	<0.001
NA	111 (46.4%)	26 (31.0%)	27 (28.4%)	
dd-cfDNA levels [%]	0.16 [0.10, 0.26]	0.33 [0.19, 0.59]	0.61 [0.27, 1.40]	<0.001
Time dd-cfDNA to EMB (d)	10.0 [6.00, 18.3]	12.0 [8.0, 16.0]	10.5 [6.00, 16.3]	0.52
pGEP levels	31.0 [27.0, 34.0]	33.0 [29.0, 35.0]	33.0 [31.8, 36.0]	<0.001
Positive pGEP	22 (20.0%)	20 (39.2%)	26 (43.3%)	0.002
NA	129 (54.0%)	33 (39.3%)	35 (36.8%)	
Time pGEP to EMB (d)	10.0 [6.00, 15.8]	11.0 [7.50, 16.0]	11.5 [6.75, 16.0]	0.41
HeartCare				<0.001
(-)pGEP/(-)dd-cfDNA	50 (46.7%)	6 (12.0%)	5 (8.3%)	<0.001
(-)pGEP/(+)dd-cfDNA	35 (32.7%)	24 (48.0%)	29 (48.3%)	0.07
(+)pGEP/(-)dd-cfDNA	13 (5.4%)	6 (12.0%)	4 (6.7%)	0.51
(+)pGEP/(+)dd-cfDNA	11 (10.3%)	14 (28.0%)	22 (36.7%)	<0.001
NA	129 (54.0%)	33 (39.3%)	35 (36.8%)	
DSA	100 (41.8%)	48 (57.1%)	47 (49.5%)	0.045
Class I	39 (16.3%)	22 (26.2%)	23 (24.2%)	0.09
Class II	87 (36.4%)	44 (52.4%)	39 (41.1%)	0.049
MFI>4000	48 (20.1%)	29 (34.5%)	27 (28.4%)	0.02
Time DSA to EMB (d)	8.00 [2.00, 20.0]	9.00 [0.750, 16.0]	8.00 [3.00, 20.5]	0.46

609

610 **D:** days; **dd-cfDNA:** donor-derived cell-free DNA; **DSA:** donor specific antibodies;

611 EMB: endomyocardial biopsy; pGEP: peripheral gene-expression profiling; MFI:

612 medium fluorescence intensity.

613

# 618 Figures and legends



**Figure 1:** multifaceted rejection approach.

.





624

Figure 3: (A) illustrates the concordance between histology and MMDx results as well as between dd-cfDNA levels and MMDx results at both thresholds [≥0.12% (B) and ≥0.20% (C)]; "DEF" accounts for definitive rejection, which includes ABMR, TCMR, and mixed rejection cases, while "BORD" refers to borderline rejection. \*(+) MMDx results include definitive and borderline rejection cases, whereas (-) MMDx includes cases of normal results and parenchymal injury.



633 immunosuppression; \*4 samples insufficient for ISHLT grading. \*\*2 cases of parenchymal injury.



# Impact of treatment on MMDx Rejection scores and Rejection-related transcripts

**Figure 5** illustrates the changes in transcripts in the follow-up MMDx after treatment. The left panel represents overall rejection scores, including antibody-mediated rejection (ABMR), injury, and T-cell-mediated rejection (TCMR). The upper right panel shows a subset of transcripts related to TCMR (ADAMDEC1, CTLA4, CXCL12, INFG, QCAT, and TCB). The lower right panel displays a subset of transcripts related to ABMR (DSAT, eDSAT, NKB, ROBO4). All transcripts show improvement after treatment in their respective rejection groups.

636

# **Overall survival** Based on MMDx results and treatment



0% Follow-up time from MMDx (months) Ó 10 Number at risk (-) MMDx 239 155 90 (+) MMDx guided treatment 81 52 21 (+) MMDx 98 52 18 No guided treatment Follow-up time from MMDx (months)

644

645 **Figure 6:** survival outcomes stratified based on MMDx results and MMDx-guided treatment.





#### Supplementary material 656





Figure 2S: [Continuation of Figure 5]. Changes in Transcripts After Treatment; Upper group
 TCMR (N=17); Lower group: ABMR (N=15).



ABMR-related transcripts: DSAT, eDSAT, NKB, ROBO4; TCMR-related transcripts:
 ADAMDEC1, CTLA4, CXCL12, INFG, QCAT, TCB; Injury-related transcripts: HT1, IRRAT,
 QCMAT, S4 Rejection-related transcript: GRIT.

671

672 **Figure 3S:** eGFR trends in the cohort of treated patients based on MMDx results at

1 month and 3 months after increasing immunosuppression.



674

675

#### 677 **Table 1S:** Baseline characteristics

Baseline characteristics	N=248
Age at transplant (years)	51.0 [39.5, 59.0]
BMI (kg/m²)	26.7 [22.8, 30.3]
Female sex	74 (29.8%)
Race/ethnicity	
White	120 (48.4%)
Black/Afro-American	69 (24.6%)
Hispanic/Latino	35 (14.1%)
Asian	12 (4.8%)
Other	4 (1.6%)
Declined	8 (3.2%)
Multiorgan	31 (12.5%)
Re-transplants	13 (5.2%)
NICM	197 (79.4%)
HTN	170 (68.5%)
HLD	133 (53.6%)
DM	88 (35.5%)
СКД	102 (41.1%)
LVAD	64 (25.8%)
tMCS	78 (31.5%)
High-risk CMV	41 (16.5%)
Donor age (years)	33.0 [26.5, 38.8]
Induction therapy	67 (27.0%)
PGD	27 (10.9%)
ECMO-postHT	26 (10.5%)
cPRA>10%	42 (16.9%)
Procurement method - DCD	11 (4.4%)
Ischemic time (hours)	3.21 [2.47, 3.97]
CAV	108 (43.5%)
CAV ISHLT grade	
0	79 (31.9%)
1	89 (35.9%)
2	8 (3.2%)
3	11 (4.4%)

.

678	CAV: Coronary Allograft Vasculopathy; CKD: Chronic Kidney Disease; cPRA: Calculated Panel
679	Reactive Antibodies; DCD: Donation after Circulatory Death; DM: Diabetes Mellitus; ECMO-
680	postHT: Extracorporeal Membrane Oxygenation post-transplant; HLD: Hyperlipidemia; HTN:
681	Hypertension; IMT: Intima-Media Thickness; LVAD: Left Ventricular Assist Device; PGD:
682	Primary Graft Dysfunction; tMCS: Temporary Mechanical Circulatory Support
683	
684	
685	
686	
687	
688	
689	
690	
691	
692	
693	
694	
695	
696	
697	
698	
699	
700	
701	
702	
703	
704	
705	
706	
707	
708	

•

# **Table 2S:** concordance and discordance between histology and MMDx

	NR-MMDx	NR-MMDx	R-MMDx	R-MMDx	
	(-) Histology	(+) Histology	(-) Histology	(+) Histology	p-value
	(N=303)	(N=17)	(N=79)	(N=15)	
dd-cfDNA≥ 0.12%	114 (66.7%)	7 (70.0%)	54 (91.5%)	8 (88.9%)	<0.001
dd-cfDNA≥ 0.20%	81 (47.4%)	6 (60.0%)	49 (83.0%)	8 (88.9%)	<0.001
NA	132 (43.6%)	7 (41.3%)	20 (25.3%)	6 (40.0%)	
(+) pGEP	40 (13.2%)	2 (11.8%)	22 (27.8%)	4 (26.7%)	0.04
NA	151 (49.8%)	9 (52.9%)	27 (34.2%)	7 (46.7%)	
dd-cfDNA %	0.19 [0.11, 0.37]	0.28 [0.13, 0.43]	0.59 [0.27, 1.30]	0.78 [0.44, 4.60]	<0.001
LVEF<50%	57 (18.8%)	5 (29.4%)	13 (16.5%)	3 (20.0%)	0.67
De-novo LVEF<50%	12 (3.9%)	3 (17.6%)	4 (5.1%)	1 (6.7%)	0.82
DSA	136 (44.9%)	11 (64.7%)	35 (44.3%)	11 (73.3%)	0.07
DSA Class I	51 (16.8%)	9 (52.9%)	16 (20.3%)	6 (40.0%)	<0.001
DSA Class II	122 (40.3%)	8 (47.1%)	28 (35.4%)	10 (66.7%)	0.15
>4000 MFI	67 (22.1%)	9 (52.9%)	16 (20.3%)	10 (66.7%)	<0.001
Histology results					
ACR>1R/1A	0 (0%)	6 (35.3%)	0 (0%)	4 (26.7%)	
pAMR>0	0 (0%)	11 (58.8%)	0 (0%)	11 (73.3%)	
pAMR>1	0 (0%)	7 (41.2%)	0 (0%)	4 (26.7%)	
MMDx results					
ABMR	0 (0%)	0 (0%)	48 (60.8%)	11 (73.3%)	
TCMR	0 (0%)	0 (0%)	26 (32.9%)	4 (26.7%)	
Mixed	0 (0%)	0 (0%)	5 (6.3%)	0 (0%)	
Borderline	73 (24.1%)	9 (52.9%)	0 (0%)	0 (0%)	
Injury	25 (8.3%)	3 (17.6%)	0 (0%)	0 (0%)	
Normal	205 (67.6%)	5 (29.4%)	0 (0%)	0 (0%)	

\* R: definitive rejection on MMDx (TCMR, ABMR, Mixed Rejection); NR: no-definitive rejection on

712 MMDx (borderline, and negative MMDx).

.

# **Table 3S:** sample characteristics stratified by MMDx results

	1 – Negative (S=239)	2 - Borderline (S=84)	3 – Definitive (S=95)	p-value
ImmuKnow levels	338 [227, 512]	288 [183, 446]	283 [199, 430]	0.01
Time ImmuKnow to MMDx (d)	7.50 [2.00, 15.0]	8.00 [3.00, 15.0]	8.50 [3.00, 14.0]	0.002
eGFR mL/min/1.73m <sup>2</sup>	66.0 [44.0, 90.0]	84.0 [56.0, 90.0	68.0 [41.0, 90.0]	<0.001
Time eGFR to MMDx (d)	0 [0, 4.50]	0 [0, 5.25]	1.00 [0, 7.50]	<0.001
NT-proBNP pg/dl	882 [341, 3100]	628 [270, 2070]	875 [384, 2630]	0.40
Time NT-proBNP to MMDx	4 [1.00, 10.0]	4 [0, 11.0]	6.00 [1.00, 12.0]	0.31
(d)				
Hs-Troponin T (TnT) ng/l	38 [15.3, 81.5]	32 [0.19, 57.5]	17.0 [11.0, 35.0]	<0.001
Time hs-TnT to EMB (d)	3.00 [1.00, 12.0]	7.00 [0.50, 14.0]	6.00 [1.00, 12.0]	0.70
Abnormal RHC	64 (27.0%)	19 (22.6%)	33 (35.1%)	0.34
Graft dysfunction	49 (20.5%)	13 (15.5%)	17 (17.9%)	0.57
De-novo LVEF<50%	26 (10.2%)	7 (8.3%)	6 (6.3%)	0.56
IS Treatment at MMDx				
Tacrolimus	209 (87.4%)	74 (88.1%)	85 (89.5%)	0.88
Mycophenolate	199 (83.3%)	71 (84.5%)	78 (82.1%)	0.91
Prednisone	190 (79.5%)	64 (76.2%)	79 (83.2%)	0.91
mTOR inhibitors	35 (14.6%)	10 (11.9%)	21 (22.1%)	0.13
Cyclosporin	24 (10.0%)	10 (11.9%)	7 (7.4%)	0.58
Belatacept	19 (7.9%)	9 (10.7%)	26 (27.4%)	<0.001
IVIG	17 (7.1%)	13 (15.5%)	12 (12.6%)	0.06
ECP	2 (0.8%)	3 (3.6%)	7 (7.4%)	0.006

D: days; ECP: Extracorporeal Photopheresis; eGFR: estimated glomerular filtration rate; hs-TnT:
 Highly Sensitive Troponin T; IS: Immunosuppressive Treatment; IVIG: Intravenous
 Immunoglobulins; mTOR inhibitors: Inhibitors of Mammalian Target of Rapamycin; RHC: Right
 Heart Catheterization

- . \_ .

.

731	Table 4S:	Changes in	transcripts in	follow-up	MMDx after	treatment in th	ne TCMR cohor	t.
		0						

	1 - Before (N=17)	2 - After (N=17)	p-value
DSAT	0.160 [-0.0200, 0.340]	0.220 [-0.0100, 0.280]	0.36
eDSAST	0 [-0.180, 0.0400]	0.0700 [-0.0800, 0.150]	0.072
NKB	0.140 [-0.0800, 0.450]	0.230 [-0.0100, 0.430]	0.87
ROBO4	9.39 [8.91, 9.65]	9.11 [8.86, 9.60]	0.55
QCAT	1.61 [1.19, 2.00]	0.770 [0.370, 1.70]	<0.001
ТСВ	2.35 [2.14, 2.82]	1.26 [0.750, 2.39]	<0.001
ADAMDEC1	6.03 [5.49, 7.50]	4.89 [4.01, 6.34]	<0.001
CXCL13	8.68 [7.18, 9.12]	7.01 [5.61, 7.81]	0.0011
IFNG	5.93 [4.77, 6.43]	4.82 [4.07, 5.27]	0.017
CTLA4	5.96 [5.59, 6.49]	4.69 [4.36, 5.88]	<0.001
GRIT	1.23 [0.910, 1.52]	0.830 [0.270, 1.49]	0.27
HT1	-0.200 [-0.270, -0.100]	-0.120 [-0.420, -0.0200]	0.022
IRRAT	0.330 [0.200, 0.630]	0.390 [0.0500, 0.600]	0.21
S4	0 [0, 0.120]	0.0400 [0, 0.190]	0.96
QCMAT	0.640 [0.420, 0.840]	0.380 [0.0700, 0.920]	0.045
ABMR_SCORE	0.0200 [0, 0.190]	0.100 [0, 0.310]	0.26
TCMR_SCORE	0.480 [0.410, 0.600]	0.200 [0.140, 0.390]	0.008
INJURY_SCORE	0 [0, 0.120]	0.0400 [0, 0.190]	0.61

ABMR-related transcripts: DSAT, eDSAT, NKB, ROBO4; TCMR-related transcripts:
ADAMDEC1, CTLA4, CXCL12, INFG, QCAT, TCB; Injury-related transcripts: HT1, IRRAT,
QCMAT, S4 Rejection-related transcript: GRIT.

745 **Table 5S:** Changes in transcripts in follow-up MMDx after treatment in the ABMR group.

746

	1 - Before (N=15)	2 - After (N=15)	p-value	
DSAT	0.500 [0.390, 0.650]	0.280 [0.0850, 0.425]	0.034	
eDSAST	0.220 [0.145, 0.325]	0.150 [-0.0150, 0.215]	0.044	
NKB	0.800 [0.605, 0.990]	0.505 [0.263, 0.628]	<0.001	
ROBO4	9.75 [9.64, 10.2]	9.47 [9.29, 9.85]	0.031	
QCAT	0.730 [0.430, 0.930]	0.260 [0.175, 0.365]	0.0097	
тсв	0.720 [0.360, 1.01]	0.390 [0.170, 0.555]	0.029	
ADAMDEC1	2.82 [2.64, 3.20]	2.90 [2.66, 3.13]	0.93	
CXCL13	4.63 [4.52, 4.76]	4.88 [4.63, 4.97]	0.11	
IFNG	4.49 [4.26, 4.62]	4.18 [4.14, 4.25]	0.0084	
CTLA4	3.98 [3.59, 4.14]	3.77 [3.49, 3.93]	0.46	
GRIT	0.680 [0.560, 0.790]	0.330 [0.190, 0.515]	0.0034	
HT1	-0.0100 [-0.0800, 0.0200]	-0.0200 [-0.0600, 0.0300]	0.31	
IRRAT	0.120 [0.0100, 0.270]	0.0400 [-0.145, 0.185]	0.069	
S4	0 [0, 0.0350]	0 [0, 0.0500]	1	
QCMAT	0.150 [0.0900, 0.280]	0.0400 [-0.100, 0.145]	0.02	
ABMR_SCORE	0.650 [0.520, 0.710]	0.370 [0.310, 0.495]	0.0097	
TCMR_SCORE	0 [0, 0.0550]	0 [0, 0.0300]	0.35	
INJURY_SCORE	0 [0, 0.0350]	0 [0, 0.0500]	1	

747

748 ABMR-related transcripts: DSAT, eDSAT, NKB, ROBO4; TCMR-related transcripts:

ADAMDEC1, CTLA4, CXCL12, INFG, QCAT, TCB; Injury-related transcripts: HT1, IRRAT,
 QCMAT, S4 Rejection-related transcript: GRIT.